* Additional information available at http://www.cdc.gov/healthyyouth/yrbs/yrbs_ methods.htm. † Quadratic and cubic trends indicate a significant but nonlinear trend in the data over time (e.g., whereas a linear trend is depicted with a straight line, a quadratic trend is depicted with a curve with one bend and a cubic trend with a curve with two bends). Trends that include significant cubic or quadratic and linear components demonstrate nonlinear variation in addition to an overall increase or decrease over time.
Understanding the trends in the prevalence of cigarette smoking among youths enables policy makers to target prevention resources more effectively. Every 2 years, CDC analyzes data from the national Youth Risk Behavior Survey (YRBS) to evaluate trends in cigarette use among high school students in the United States. This report updates a previous report (1) and describes results of CDC's 2010 analysis of YRBS data from 1991-2009 for three measures: ever smoked cigarettes, current cigarette use, and current frequent cigarette use. For ever smoked cigarettes, the prevalence did not change from 1991 (70.1%) to 1999 (70.4%), declined to 58.4% in 2003, and then declined more gradually, to 46.3% in 2009. For current cigarette use, the prevalence increased from 27.5% in 1991 to 36.4% in 1997, declined to 21.9% in 2003, and then declined more gradually, to 19.5% in 2009. For current frequent cigarette use, the prevalence increased from 12.7% in 1991 to 16.8% in 1999, declined to 9.7% in 2003, and then declined more gradually, to 7.3% in 2009. For all three measures, rates began to decline in the late 1990s, but the rate of decline slowed during [2003] [2004] [2005] [2006] [2007] [2008] [2009] . To increase the rate of decline in cigarette use among high school students, reductions in advertising, promotions, and commercial availability of tobacco products should be combined with full implementation of communitywide, comprehensive tobacco control programs (2) (3) (4) (5) .
The biennial national YRBS, a component of CDC's Youth Risk Behavior Surveillance System, used independent, threestage cluster samples for the 1991-2009 surveys to obtain cross-sectional data representative of public and private school students in grades 9-12 in all 50 states and the District of Columbia.* For each survey, students completed anonymous, self-administered questionnaires that included identically worded questions about cigarette use. During 1991-2009, the number of participating schools ranged from 110 to 159, and the number of participating students ranged from 10,904 to 16,410. School response rates ranged from 70% to 81%, student response rates ranged from 83% to 90%, and the overall response rates ranged from 60% to 71%.
For this analysis, ever smoked cigarettes was defined as ever trying cigarette smoking, even one or two puffs; current cigarette use was defined as smoking cigarettes on at least 1 day during the 30 days before the survey; and current frequent cigarette use was defined as smoking cigarettes on 20 or more days during the 30 days before the survey. Race/ethnicity data were analyzed only for non-Hispanic black, non-Hispanic white, and Hispanic students (who might be of any race); the numbers of students from other racial/ethnic groups were too small for meaningful analysis. Data were weighted to provide national estimates, and the statistical software used for all data analyses accounted for the complex sample design. Temporal changes were analyzed using logistic regression analyses, which controlled for sex, race/ethnicity, and grade and simultaneously assessed linear, quadratic, and cubic time effects (p<0.05). † Significant linear, quadratic, and cubic effects were detected for all three measures (Table 1 and Figure 1 ). The percentage of students who ever smoked cigarettes did not change from cigarette use increased from 1991 to 1999, declined from 1999 to 2003, and then remained stable. Among black female students, only linear and quadratic effects were observed, indicating that the prevalence of current cigarette use increased from 1991 to 1999 and then declined, with no slowing or leveling off.
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Editorial Note
The findings in this report show that for three measures of cigarette use (ever smoked cigarettes, current cigarette use, and current frequent cigarette use), rates among high school students began to decline in the late 1990s, but the rate of decline slowed during [2003] [2004] [2005] [2006] [2007] [2008] [2009] . These trends are consistent with trends for 30-day and daily cigarette use reported from the Monitoring the Future survey (an ongoing national study of the behaviors, attitudes, and values of 8th-, 10th-, and 12th-grade students), which also showed declines starting in the late 1990s but gradual declines most recently (6) . As a result of the slow declines in youth smoking described in this report, the Healthy For current cigarette use, trend analyses were conducted by sex, race/ethnicity, and grade in school (Figures 2 and 3 ). Significant linear, quadratic, and cubic effects similar to the overall analysis were observed for current cigarette use among female students overall, white female students, black students overall, black male students, 9th-grade students, and 10th-grade students (Table 2 ). Among male students overall, white students overall, white male students, Hispanic male students, and 11th-grade students, current cigarette use increased from 1991 to 1997, declined from 1997 to 2003, and then remained stable. Among Hispanic students overall and Hispanic female students, current cigarette use increased from 1991 to 1995, declined from 1995 to 2003, and then remained stable. Among 12th-grade students, current free environments, programs that promote changes in social norms, and comprehensive communitywide and school-based tobacco-use prevention policies) (2) (3) (4) (5) .
The findings in this report are subject to at least two limitations. First, these data apply only to youths who attend school and, therefore, are not representative of all persons in this age group. Nationwide, in 2007, of persons aged 16-17 years, approximately 4% were not enrolled in a high school program and had not completed high school (9) . Second, the extent of underreporting or overreporting of cigarette use cannot be determined, although the survey questions demonstrate good test-retest reliability (10) .
People 2010 national health objective to reduce the prevalence of current cigarette use among high school students to ≤16% § has not been met.
The findings in this report also show that since 2003 the rate of decline in current cigarette use slowed or leveled off for all racial/ethnic and sex subgroups except black female students, for which no slowing or leveling off occurred in the rate of decline after 1999. Cigarette smoking rates reflect complex and interrelated individual, social, and environmental factors (4, 7) . More detailed research is needed to explain why current cigarette use during 2003-2009 declined more slowly among some racial/ethnic and sex subgroups of high school students but remained stable among others.
The impact of tobacco advertising and promotion activities on youth smoking initiation has been documented previously (8) . The increase in current cigarette use among high school students during the early to mid-1990s observed in this and other surveys might have resulted from expanded tobacco company promotional efforts, including discounted prices on cigarette brands most often smoked by adolescents, depictions of tobacco use in movies, distribution of nontobacco products with company symbols (e.g., hats and T-shirts), and sponsorship of music concerts and other youth-focused events (7) . Reductions in advertising, promotions, and commercial availability of tobacco products should be combined with expanded counter-advertising mass media campaigns and implemented with other well-documented and effective strategies (e.g., higher prices for tobacco products through increases in excise taxes, tobacco- Administration (FDA) additional authority to regulate the tobacco industry. The Act imposes specific marketing, labeling, and advertising requirements, and establishes restrictions on youth access and promotional practices that are particularly attractive to youth. The provisions of the Act offer opportunities for FDA to work as a partner in tobacco prevention and control (e.g., through collaborations with CDC and other federal and state agencies) (5) . As suggested by the Institute of Medicine, the regulation of tobacco products is an important component of a comprehensive national tobacco prevention and control strategy that will complement and strengthen the impact of traditional, evidence-based interventions (4).
What is already known on this topic?
National data show that the prevalence of cigarette use among youths began to decline in the late 1990s.
What is added by this report?
The findings in this report show that for three measures of cigarette use (ever smoked cigarettes, current cigarette use, and current frequent cigarette use), rates among high school students began to decline in the late 1990s, but the rate of decline slowed during 2003-2009. What are the implications for public health practice?
To reduce the adverse health consequences associated with tobacco use, the most effective evidencebased strategies to reduce initiation of tobacco use among youths should be implemented nationwide, including higher prices for tobacco products, tobacco-free environment policies, and counteradvertising mass media campaigns. Nigeria has maintained a high incidence of wild poliovirus (WPV) cases attributed to persistently high proportions of under-and unimmunized children, and, for many years, the country has served as a reservoir for substantial international spread (1) . In 2008, Nigeria reported 798 polio cases, the highest number of any country in the world (2) . This report provides an update on poliovirus epidemiology in Nigeria during the past 18 months, January 2009-June 2010, and describes activities planned to interrupt transmission. Reported WPV cases in Nigeria decreased to 388 during 2009 (24% of global cases), and WPV incidence in Nigeria reached an all-time low during January-June 2010, with only three reported cases. Cases of circulating type 2 vaccine-derived poliovirus (cVDPV2), which first occurred in Nigeria in 2005 (3), also declined, from 148 during the 12 months of 2009, to eight during the 6-month period, January-June 2010. One indicator of the effectiveness of immunization activities is the proportion of children with nonpolio acute flaccid paralysis (AFP) who never have received oral poliovirus vaccine (OPV). In seven high-incidence northern states of Nigeria, this proportion declined from 17.6% in 2008 to 10.7% in 2009. During 2009-2010, increased engagement of traditional, religious, and political leaders has improved community acceptance of vaccination and implementation of high-quality supplementary immunization activities (SIAs). Enhanced surveillance for polioviruses, further strengthened implementation of SIAs, and immediate immunization responses to newly identified WPV and cVDPV2 cases will be pivotal in interrupting WPV and cVDPV2 transmission in Nigeria.
Immunization Activities
Routine immunization against polio in Nigeria consists of trivalent OPV (tOPV, types 1, 2, and 3) at birth and at ages 6, 10, and 14 weeks. Immunization coverage is measured using both administrative data (estimated doses administered per targeted child population, determined by official census numbers) and coverage surveys. In 2009, using administrative data, national routine immunization coverage of children by age 12 months with three tOPV doses was 63% (range by state: 35%-90%) (4). Using coverage surveys, the estimated national coverage with three tOPV doses at 12-23 months was 39%, but lower in the northeast (28.6%) and northwest (24.3%) areas of Nigeria, including the seven high-incidence northern states (5) .* In addition to routine immunization, Nigeria conducts SIAs † for polio eradication using monovalent OPV type 1 (mOPV1), monovalent OPV type 3 (mOPV3), bivalent OPV types 1 and 3 (bOPV), or tOPV. Monovalent vaccines are more effective than tOPV in providing protection against the corresponding WPV serotype; bOPV is nearly equivalent to mOPV and superior to tOPV in producing seroconversion to WPV1 and WPV3 (6) . Three national SIAs were conducted in 2009, using mOPV3, mOPV1, and tOPV. Five subnational SIAs were conducted in 2009, each using mOPV1, mOPV3, tOPV, or both mOPV1 and mOPV3. During January-June 2010, two national SIAs were conducted, one with bOPV and one with tOPV; bOPV, mOPV1, and mOPV3 were used in three subnational SIAs (Figure 1 ).
Vaccination histories of children with nonpolio AFP are used to estimate OPV coverage among the population of children aged 6-59 months. The proportion of children with nonpolio AFP reported to have never received an OPV dose (zero-dose children) from the seven high-incidence northern states declined from 17.6% in 2008 to 10.7% in 2009 (range: 0%-17.0%), with the highest proportions occurring in Zamfara and Kano states (Table) . In contrast, the proportion of reported zero-dose children was 2.2% in 13 other northern states and 1.8% in 17 southern states in 2009. The proportion of children with nonpolio AFP reported to have received ≥4 OPV doses was 37.4% in the seven high-incidence northern states and 60.8% for the entire country. mOPV1/mOPV3 bOPV/mOPV3 § AFP cases in children aged <15 years and suspected poliomyelitis in persons of any age are reported and investigated, with laboratory testing, as possible polio. WHO operational targets for countries at high risk for poliovirus transmission are a nonpolio AFP rate of at least two cases per 100,000 population aged <15 years at each subnational level and adequate stool specimen collection for >80% of AFP cases (i.e., two specimens collected at least 24 hours apart, both within 14 days of paralysis onset, and shipped on ice or frozen ice packs to a WHO-accredited laboratory and arriving at the laboratory in good condition). All WPV isolates undergo partial genomic sequencing to determine genetic relatedness. Each 1% difference between two isolates correlates with approximately 1 year of undetected circulation between the specific chains of transmission. Differences greater than 1.5% indicate potential quality issues for surveillance. Three of the seven WPV1 isolates from July-December 2009 cases and the one WPV1 isolate from 2010 exhibited >1.5% divergence from the closest predecessor. Similarly, nine of the 24 (38%) WPV3 isolates from July-December 2009 and both 2010 WPV3 exhibited ≥1.5% divergence. 
Progress Toward Poliomyelitis Eradication
WPV and cVDPV Incidence
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Editorial Note
Since 2003, Nigeria has served as the major reservoir for WPV1 and WPV3 circulation in West Africa and Central Africa (7) . Over the past 8 years, WPV of Nigerian origin has been imported into 26 countries in Africa, the Middle East, and Asia, and has led to reestablished transmission (>12 months) in Chad and Sudan.
Factors related to high WPV incidence in Nigeria during the last decade have included loss of public confidence in OPV during 2003-2004 (8) , longstanding insufficiencies in health infrastructure resulting in low routine vaccination coverage, and poorly implemented SIAs that have failed to reach >80% of children in high-risk states. With substantial reductions in WPV1, WPV3, and cVDPV2 cases during January-June 2010 compared with the same period in 2009, Nigeria has shown substantial progress, suggesting improvements in vaccine coverage with highquality SIAs. The increased engagement of traditional, religious, and political leadership at the federal, state, and local levels has been instrumental in improving vaccine acceptance and SIA implementation. If this progress can be sustained throughout the upcoming season (July-September), during which WPV transmission is traditionally high, WPV transmission in Nigeria could be disrupted in the near future. Progress elsewhere, including successful implementation of synchronized SIAs in West Africa and Central Africa to stem regional WPV circulation, would remove a potential threat of reimportation into Nigeria and ultimately lead to a polio-free Africa. However, multiple challenges must be overcome to sustain the gains in Nigeria.
Within the seven high-incidence northern states, a high proportion of children remain at risk as a result of low routine immunization coverage and high birth rates. This report indicates that, during 2008-2009, a substantial drop occurred in the proportion of children with nonpolio AFP who had received no doses of vaccine (i.e., from 17.6% in 2008 to 10.7% in 2009) in the seven high-incidence states. However, even with this decrease, in 2009, a majority of such children (50.7%) remained undervaccinated with 1-3 doses of OPV. Until the proportion of children vaccinated with ≥4 doses is >80% and the proportion of zerodose children is <10% in each state, the risk remains that WPV transmission will continue (9) .
The quality of SIA implementation remains variable and highly dependent on LGA commitment and resources, including timely disbursement of funds in support of SIAs. Successful implementation of SIAs planned for the remainder of 2010 will require ongoing engagement of LGA leadership and supervision, with close monitoring of performance indicators at the LGA, state, and federal levels. Since emerging in 2005-2006, cVDPV2 continues to circulate in northern Nigeria. Continued use of high-quality SIAs with tOPV will be needed to further control and eliminate cVDPV2 transmission, while routine immunization services are strengthened. Any new WPV case should trigger rapid, type-specific vaccination responses ("mop-up" SIAs).
Genomic sequence analysis indicates that some chains of WPV transmission during 2009-2010 have not been detected for more than a year, suggesting limitations in surveillance quality despite AFP surveillance performance indicators meeting or What is already known on this topic?
In 2008, 798 cases of wild poliovirus (WPV) (48% of global cases) were reported in Nigeria, one of four remaining countries (including India, Pakistan, and Afghanistan) that have never eliminated WPV transmission of both serotypes 1 and 3.
From 2008 to 2009, cases of WPV in Nigeria declined substantially (from 798 cases to 388), now accounting for <1% of reported global WPV cases, and during the first 6 months of 2010, only three WPV cases were reported. Among children with nonpolio acute flaccid paralysis, the decline from 17.6% in 2008 to 10.7% in 2009 of zero-dose children in high-incidence northern states indicates that population immunity might be steadily increasing in areas that traditionally have been responsible for extensive WPV transmission.
What are the implications for public health practice?
With sustained support of traditional, religious, and political leaders to improve implementation of polio vaccination activities and to improve surveillance for polio cases, Nigeria has the potential to eliminate WPV transmission in the near future.
exceeding targets at national and virtually all state levels. Surveillance gaps might be occurring among specific subpopulations such as migrants in northern Nigeria, including Fulani nomads, who have limited access to immunization activities and health-care providers. Further efforts to enhance and supplement AFP surveillance to detect WPV and cVDPV should include seeking reports from nontraditional healers, testing waste water for polioviruses, and identifying and improving surveillance in LGAs not meeting performance criteria.
Despite recent declines in both incidence and mortality, colorectal cancer (CRC) remains the second most common cause of cancer deaths after lung cancer in the United States (1) and the leading cause of cancer deaths among nonsmokers. In 2006 (the most recent data available), 139,127 people were diagnosed with colorectal cancer, and 53,196 people died (1). Screening for colorectal cancer is effective in reducing incidence and mortality by removal of premalignant polyps and through early detection and treatment of CDC Vital Signs is a new series of MMWR reports that will announce the latest results for key public health indicators.
Vital Signs: Colorectal Cancer Screening Among Adults Aged 50-75 Years -United States, 2008
cancer (2). CRC screening prevalence has improved over the past decade (3); however, in 2006, approximately 30% of eligible U.S. residents had never been screened for CRC (3). This Vital Signs report updates screening prevalence in the United States using data from the 2008 Behavioral Risk Factor Surveillance System (BRFSS) survey for persons aged 50-75 years, based on recommendations for up-to-date CRC screening from the U.S. Preventive Services Task Force (USPSTF) (4).
Methods
BRFSS is a state-based, random-digit dialed telephone survey of the civilian, noninstitutionalized adult population that collects information on use declined from 20.9% of CRC screening in 2002 to 14.1% in 2008.
Conclusions and Comment
The results in this Vital Signs report indicate that the prevalence of up-to-date CRC screening in the United States is continuing to increase. An increase (from 38% in 2000 to 53% in 2008) also has been reported using National Health Interview Survey data (6) . However, in 2008, certain populations in the United States remained underscreened, including those with lower socioeconomic status, Hispanics, and those without health insurance. Multiple factors might explain these differences, including patient education and income, as well as provider and clinical systems factors. As in previous surveys, the 2008 survey indicated notable geographic differences in CRC screening prevalence. The reasons for these geographic differences remain unknown, but screening capacity, lack of physician availability, and patient factors including income, education, and lack of awareness have been proposed as reasons (6) .
CRC screening rates continue to increase in the United States. Additional improvements in screening prevalence might have substantive impact on CRC mortality. Statistical modeling indicates that, if current trends in health behaviors, screening, and treatment continue, U.S. residents can expect to see a 36% decrease in the CRC mortality rate by 2020, compared with 2000 (7) .
Insufficient evidence exists to recommend "one best" test for CRC screening. Several proven, effective tests exist and are recommended by USPSTF, including annual FOBT, sigmoidoscopy every 5 years,
Key Points for the Public
• Over 53,000 U.S. residents die each year from colorectal cancer.
• 1,900 deaths could be prevented each year for every 10% increase in colonoscopy screening.
• Only 36% of men and women without health insurance are up-to-date with colorectal cancer screening.
• Additional information is available at http://www.cdc.gov/vitalsigns.
health risk behaviors, preventive health practices, and health-care access in the United States (5). Every 2 years (in even numbered years), respondents aged ≥50 years are asked whether they have ever used a "special kit at home to determine whether the stool contains blood (fecal occult blood test [FOBT] )," whether they have ever had a "tube inserted into the rectum to view the colon for signs of cancer or other health problems (sigmoidoscopy or colonoscopy)," and when these tests were last performed. CDC calculated the prevalence of adults who reported having had an FOBT within the past year or lower endoscopy (i.e., sigmoidoscopy or colonoscopy) within the preceding 10 years, as was done in previous reports (3 
Results
The 2008 BRFSS survey was administered to 414,509 respondents, of whom 201,157 were aged 50-75 years. The overall, age-adjusted combined upto-date CRC screening (FOBT and lower endoscopy) prevalence for the United States was 62.9% among adult respondents aged 50-75 years (Table) . Among the lowest screening prevalences were those reported by persons aged 50-59 years (53.9%), Hispanics (49.8%), persons with lower income (47.6%), those with less than a high school education (46.1%), and those without health insurance (35.6%). Similar patterns were noted for FOBT in the preceding year and for lower endoscopy in the preceding 10 years. The percentage of persons up-to-date with CRC screening ranged from 53.2% in Oklahoma to 74.1% in Massachusetts (Figure 1) . States with the highest screening prevalence were concentrated in the northeastern United States. CRC screening increased from 51.9% in 2002 to 62.9% in 2008 (Figure 2) . During that period, use of endoscopy increased, while FOBT and colonoscopy every 10 years (4). In addition to maximizing prevalence of CRC screening to reduce morbidity and mortality, ensuring proper follow-up of abnormal results is important to maximize the benefits of screening (4) .
The findings in this report are subject to at least three limitations. First, because BRFSS is a telephone survey of residential households, only adults in households with landline telephones are represented; therefore, the results might not be representative of the U.S. population. Evidence suggests that adults living in wireless-only households tend to be younger and have lower incomes, and are more likely to be members of minority populations, which might result in either underestimates or overestimates. Second, responses are self-reported and not confirmed by review of medical records. Finally, the survey response rate was low, which increases the risk for response bias.
Policy changes in the Patient Protection and Affordable Care Act are expected to remove financial barriers to CRC screening by expanding insurance coverage and eliminating cost sharing in Medicare and private plans, but additional barriers remain (8) . Evidence-based, systems-change interventions, including client and provider reminders to ensure test completion and receipt of follow-up care, have been shown by the Guide to Community Preventive Services* to increase CRC screening; however, these approaches have not been widely adopted in clinical Preventive Services, which has identified evidencebased interventions to increase cancer screening in communities by targeting providers and the general population. Full implementation of these recommendations, including a focus on reaching disadvantaged populations, can achieve the goal of more complete population coverage.
Surveillance of cancer screening and diagnostic activities currently is limited to population surveys and is only collected every other year by BRFSS. Additional surveillance efforts might guide population-based outreach, identify and target unscreened populations, and ensure adequate follow-up (10) . CDC and state and local health departments should develop and monitor centralized population-based registries of persons eligible for screening, provide appropriate outreach, and ensure adequate followup. These registries could be developed to track and promote screening awareness and subsequent utilization through communication media (e.g., telephone, mail, or electronic reminders) or use of peer outreach. Registries of underserved populations, including Medicaid enrollees and those without a regular provider, could be used to promote screening among persons in vulnerable populations at greater risk. 
Conclusions:
In recent years, mammography rates have plateaued. Critical gaps in screening remain for certain racial/ethnic groups and lower socioeconomic groups, and for the uninsured.
Implications for Public Health Practice:
Health-care reform is likely to increase access by increasing insurance coverage and by reducing out-of-pocket costs for mammography screening. Widespread implementation of evidence-based interventions also will be needed to increase screening rates. These include patient and provider reminders to schedule a mammogram, use of small media (e.g., videos, letters, brochures, and flyers), one-on-one education of women, and reduction of structural barriers (e.g., more convenient hours and attention to language, health literacy, and cultural factors).
Methods
BRFSS is a state-based, random-digit-dialed telephone survey of the civilian, noninstitutionalized adult population that collects information on health risk behaviors, preventive health practices, and health-care access in the United States (6). Every 2 years (even numbered years), adult female respondents are asked whether they have ever had a mammogram. Respondents who answer "yes" are then asked how long it has been since their last mammogram. For this report, breast cancer screening prevalence was calculated for women aged 50-74 years based on United States Preventive Services Task Force (USPSTF) recommendations, which considers women to be up-todate if they received a mammogram in the preceding 2 years (7). Respondents who refused to answer, had prevalences reported were those by women aged 50-59 years (79.9%), persons who did not finish high school (72.6%), American Indian/Alaska Natives (70.4%), those with annual household income <$15,000 (69.4%), and those without health insurance (56.3%). Mammography screening prevalence varied by state, with the highest mammography use in the northeastern United States. Among states, screening prevalence ranged from 72.1% in Nevada to 89.8% in Massachusetts (Figure 1) . Nationally, up-to-date mammography screening increased from 77.5% in 1997 to 81.1% in 2008 (Figure 2 ).
Conclusions and Comment
After mammography was shown to be effective in lowering morbidity and mortality from breast cancer in the early 1990s, it was adopted rapidly for the early detection of breast cancer (3). However, as this Vital Signs report confirms, mammography utilization has leveled off in the last decade (4, 5) . Other populationbased surveys have shown a similar plateau in rates. Nonetheless, approximately 7 million eligible women in the United States are not being screened regularly, and they remain at greater risk of death from breast cancer. One recent report estimated that as many as 560 breast cancer deaths could be prevented each year with each 5% increase in mammography (8) . One successful program that reaches out to minority, low income, uninsured women is the National Breast and Cervical Cancer Early Detection Program. † The program has provided high quality screening, diagnostic and treatment services for the past 20 years.
Mammography utilization is influenced by multiple factors, including patient and provider characteristics, health-care norms, and access to and availability of health-care services. Similar to previous a missing answer, or answered "don't know/not sure" were excluded.
The median Council of American Survey and Research Organizations (CASRO) response rate was 53.3%, and the median CASRO cooperation rate was 75.0% (6) . Data were weighted to the age, sex, and racial and ethnic distribution of each state's adult population using intercensal estimates and were age-standardized to the 2008 BRFSS female population.
Results
In 2008, the BRFSS survey was administered to 414,509 respondents, of whom 120,095 were women aged 50-74 years. The age-adjusted prevalence of up-to-date mammography for women overall in the United States was 81.1% (Table) . Among the lowest analyses, the analysis in this report found pockets of mammography underscreening among several large U.S. populations. For example, the screening rate varied considerably by geography and was lowest in west-central states, the states with the lowest population densities § as well as the states with the fewest mammography facilities. ¶ A study from Texas highlighted the association between mammography supply and mammography use at the county level. Counties with no mammography units had the lowest mammography utilization (9) . The passage of the Patient Protection and Affordability Act should remove the financial barrier to mammography screening by expanding coverage and eliminating cost sharing in Medicare and private plans; however, barriers remain. For example, in 2008 the difference in mammography prevalence between women with and without health insurance was 27.5%. Even among women with health insurance, 16.2% had not received mammography in the preceding 2 years. Similar differences in receipt of mammography by insurance status were noted in a 2009 study (9) . These findings suggest new roles for public health to improve screening through increased education of women and providers, and through additional targeted outreach to underscreened groups including lower SES, uninsured and select minority groups. Several evidence-based interventions are recommended by the Guide to Community Preventive Services to increase mammography screening in communities.** These include sending client reminders to women, using small media (e.g., videos, letters, flyers, and brochures), and reducing structural barriers (e.g., providing more convenient hours and increasing
Key Points for the Public
• One in five women aged 50-74 is not up-to-date with mammograms.
• Over 40,000 U.S. women die each year from breast cancer.
• 560 deaths can be prevented each year for each 5% increase in mammography.
• attention to language, health literacy, and cultural factors). Surveillance with targeted outreach, case management, and quality assurance through systems change are productive future roles for public health agencies to improve the delivery of clinical preventive services in the era of health reform. The findings in this report are subject to at least three limitations. First, because BRFSS is a telephone survey of residential households, only women in households with landline telephones participated; therefore, the results might not be representative of all women. Second, responses are self-reported and not confirmed by review of medical records. Finally, the survey response rate was low, which increases the risk for response bias.
Many factors influence a woman's intent and ability to access screening services, including socioeconomic status, awareness of the benefits of screening, and mammography acceptability and availability (10) . However, the most common reason women give for not having a mammogram is that no one recommended the test; therefore, health-care providers have the most important role in increasing the prevalence of up-to-date mammography among women in the United States (10).
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birthing hospitals and local health departments to support postpartum vaccination of mothers and close contacts of newborns. 
Salmonella Newport Infections Associated with Consumption of Unpasteurized Milk -Utah, April-June 2010
On April 29, 2010, the Utah Department of Health (UDOH) was notified of three cases of Salmonella enterica serotype Newport infection. The three patients recently had consumed unpasteurized milk purchased from a store in northern Utah (store A). In Utah, unpasteurized milk can be sold legally at licensed dairies or by licensed dairies at dairy-owned retail stores meeting specific requirements (1). A central Utah dairy licensed to sell unpasteurized milk (dairy A) owns and sells unpasteurized milk at store A and a second northern Utah store (store B). By May 3, 2010, three additional patients with S. Newport infections had been reported; all recently had consumed unpasteurized milk purchased from store A. UDOH notified the Utah Department of Agriculture and Food (UDAF) of the suspected association between illness and unpasteurized milk consumption, and UDAF suspended sales of unpasteurized milk at the two stores on May 3, 2010.
During April 29-June 3, 2010, a total of 10 S. Newport cases were reported to UDOH; all 10 patients had consumed unpasteurized milk from store A (seven patients) or store B (three patients). The patients ranged in age from 2 to 56 years (median: 21 years); six were female. One patient was
Pertussis -California, January-June 2010
The number of pertussis cases reported to the California Department of Public Health (CDPH) has increased substantially during 2010. The increase in cases was first noted in late March among patients admitted to a children's hospital. During January 1-June 30, 2010, a total of 1,337 cases were reported, a 418% increase from the 258 cases reported during the same period in 2009. All cases either met the Council of State and Territorial Epidemiologists definitions for confirmed or probable pertussis or had an acute cough illness and Bordetella pertussis-specific nucleic acid detected by polymerase chain reaction from nasopharyngeal specimens (1) .
During January-June in California, the incidence of pertussis was 3.4 cases per 100,000 population. County rates ranged from zero to 76.9 cases per 100,000 (median: 2.0 cases). By age group, incidence was highest (38.5 cases per 100,000) among infants aged <1 year; 89% of cases were among infants aged <6 months, who are too young to be fully immunized. Incidence among children aged 7-9 years and 10-18 years was 10.1 cases and 9.3 cases per 100,000, respectively.
Of 634 case reports with available data, 105 (16.6%) patients were hospitalized, of whom 66 (62.9%) were aged <3 months. Incidence among Hispanic infants (49.8 cases per 100,000) was higher than among other racial/ethnic populations. Five deaths were reported, all in previously healthy Hispanic infants aged <2 months at disease onset; none had received any pertussis-containing vaccines.
The incidence of pertussis is cyclical, with peaks occurring every 3-5 years in the United States (2 From 1988 to 2006-2008, the percentage of never-married teenage females (ages 15-19 years) who ever had sexual intercourse declined from 51% to 42%, and the percentage for never-married teenage males declined from 60% to 43%. In 1988, teenage males were more likely than teenage females to have ever have had sexual intercourse, but by 2006-2008, the percentages were equivalent. Table II. † † Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting influences the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data management system is completed. Data for HIV/AIDS, when available, are displayed in Table IV, respect to acute and chronic Q fever cases. ¶ ¶ ¶ The one rubella case reported for the current week was unknown. **** Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases.
† † † † Updated weekly from reports to the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. § § § § There was one case of viral hemorrhagic fever reported during week 12. The one case report was confirmed as lassa fever. See Table II for dengue hemorrhagic fever. American Samoa Table IV , which appears quarterly. † Contains data reported through the National Electronic Disease Surveillance System (NEDSS). -0  6  12  4  -0  6  22  37  -0  6  21  26  Puerto Rico  -0  2  2  18  -0  5  8  19  -0 13  11  24  227  224  75  62  258  1,244  1,621  10  6  15  134  166  Delaware  -0  5  8  8  11  12  65  297  393  -0  1  2  1  District of Columbia  -0  4  12  13  -0  4  8  32  -0  3  6  6  Florida  8  4  10  86  70  6  2  11  32  17  3  2  7  55  41  Georgia  -1  4  23  25  -0  6  4  27  -0  6  3  36  Maryland  †  5  3  12  52  56  40  27  134  569  793  2  1  13  28  42  North Carolina  -0  5  2  27  -0  6  12  56  -0  3  5  18  South Carolina  †  -0  2  5  3  -1  3  17  17  -0  1  3  1  Virginia  †  -1  6  34  22  18  14  79  290  253  5  1  5  32  20  West Virginia  -0  3  5  --0  33  15  33  -0  2 -1 3  2  12  58  55  1  1  4  22  11  -0  4  11  20  Alabama  †  -0  2  7  9  -0  1  -1  -0  3  2  6  Kentucky  -0  3  10  23  -0  1  1  1  -0  3  3  5  Mississippi  -0  2  5  2  -0  0  ---0  1  -2  Tennessee  †  3  1  9  36  21  1  1  4  21  9  -0  1  6  7 W.S. Central  -2  14  41  52  -3  44  31  51  -1  31  47  20  Arkansas  †  -0  2  8  4  -0  0  ---0  1  1  2  Louisiana  -0  3  1  5  -0  0  ---0  1  -4  Oklahoma  -0  4  6  3  -0  2  ---0  1  3  -Texas  †  -1  10  26  40  -3  42  31  51  -1  30  43  14   Mountain  3  3  8  71  57  -0  4  6  24  -1  6  20  17  Arizona  3  1  4  22  23  -0  1  1  1  -0  2  11  2  Colorado  -1  5  17  7  -0  1  1  --0  3  3  11  Idaho  †  -0  2  -1  -0  3 6  4  19  137  83  -5  10  112  56  2  3  19  56  60  Alaska  -0  0  -1  -0  1  1  3  -0  1  2  2  California  3  3  19  119  63  -3  9  75  31  1  1  13  34  45  Hawaii  -0  1  1  1  N  0  0  N  N  -0  0  -1  Oregon  1  0  3  6  7  -1  4  32  19  -0  1  5  7  Washington  2  0  4  11  11  -0  3  4  3  1  0  5  15  5 American Table I . § Contains data reported through the National Electronic Disease Surveillance System (NEDSS). 1 -0  1  ---0  110  -43  Louisiana  -0  0  ---0  0  -2  Oklahoma  -0  3  --1  0  287  9  10  Texas  §  -0  1  1  1  -0  11  4  12   Mountain  -0  2  2  7  -0  3  4  13  Arizona  -0  2  -2  -0  2  1  5  Colorado  -0  1  ---0 21  66  285  1,723  3,245  -0  19  -7  -0  6  -1  Arkansas  §  -3  32  106  313  -0  1  -2  -0  0  --Louisiana  -2  10  64  73  -0  2  -2  -0  4  --Oklahoma  N  0  0  N  N  -0  2  ---0  2  --Texas  §  21  56  272  1,553  2,859  -0  16  -3  -0  4  -1  Mountain  -25  48  628  1,231  -0  12  -7  -0  17  -9  Arizona  -0  0  ---0  4  -3  -0  2  -1  Colorado  §  -10  41  239  662  -0  7  ---0  14  -2  Idaho  §  N  0  0  N  N  -0  3  -1  -0  5  -1  Montana  §  -3  17  129  108  -0  1  ---0  1  --Nevada  §  N  0  0  N  N  -0  2  -3  -0  1  -3  New Mexico  §  -1  7  59  86  -0  2  ---0  1  --Utah  -6  22  188  375  -0  1  ---0  0  -1  Wyoming  §  -0  3  13  --0  1  ---0 Table IV , which appears quarterly. † Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for California serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I . § Contains data reported through the National Electronic Disease Surveillance System (NEDSS). ¶ Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and influenzaassociated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/ncphi/disss/nndss/phs/infdis.htm.
S. Atlantic
E.S. Central
1 6 - 0 1 - 1 Montana † - 0 1 4 4 - 0 1 - 1 - 0 3 1 1 Nevada † - 0 2 15 6 - 0 2 - 8 - 0 1 2 - New Mexico † - 0 2 2 1 - 0 1 1 1 - 0 0 - - Utah - 0 3 9 14 - 0 1 2 6 - 0 1 3 2 Wyoming † - 0 2 2 1 - 0 1 - 1 - 0 0 - - PacificSamoa - 0 0 - - N 0 0 N N - 0 0 - - C.N.M.I. - - - - - - - - - - - - - - - Guam - 0 0 - - - 0 0 - - - 0 0 - - Puerto Rico - 0 1 - - N 0 0 N N - 0 2 1 1 U.S. Virgin Islands - 0 0 - - - 0 0 - - - 0 0 - - C.N.E.N. Central - 20 - - American Samoa - 0 0 - - - 0 0 - - N 0 0 N N C.N.M.I. - - - - - - - - - - - - - - - Guam - 0 0 - - - 0 2 - - - 0 0 - - Puerto Rico - 0 1 - - - 0 0 - 1 1 1 3 23 23 U.S. Virgin Islands - 0 0 - - - 0 0 - - - 0 0 - - C.N.1 1 2 - - 0 0 - - - 1 1 1 3 C.N.M.I. - - - - - - - - - - - - - - - Guam - 0 2 2 5 - 0 0 - - - 0 3 1 3 Puerto Rico 4 7 39 101 260 - 0 0 - - - 0 1 - 7 U.S. Virgin Islands - 0 0 - - - 0 0 - - - 0 0 - - C.
